MedicaidPrior AuthLow impact
Trisenox® (arsenic trioxide) (New)
Humana·LA · Hematology, Oncology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Trisenox (arsenic trioxide) effective March 1, 2026 for Louisiana Medicaid patients. Coverage requires diagnosis of acute promyelocytic leukemia (APL) and use for induction therapy, consolidation therapy, or relapsed disease.
Action Required
Before March 1, 2026: Billing team must implement prior authorization requirements for Trisenox (arsenic trioxide) prescriptions for Louisiana Medicaid patients. Verify patient has APL diagnosis and intended use is for induction therapy, consolidation therapy, or relapsed disease before submitting claims. Update system to flag this medication for prior auth review.